Title: Use of Early-TIPS for High-Risk Variceal Bleeding. Results of a post-RCT Surveillance Study
Authors: Garcia-Pagán, J C
Di Pascoli, M
Caca, K
Laleman, Wim
Bureau, C
Appenrodt, B
Luca, A
Zipprich, A
Abraldes, J G
Nevens, Frederik
Vinel, J P
Sauerbruch, T
Bosch, J
Issue Date: Jan-2013
Publisher: Elsevier Science Publishers
Host Document: Journal of Hepatology vol:58 issue:1 pages:45-50
Conference: 47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) location:Barcelona, Spain date:April, 18-22
Abstract: BACKGROUND: In a recent randomized international clinical trial (RCT) in high-risk cirrhotic patients with acute variceal bleeding, the early use of transjugular intrahepatic portosystemic shunt (TIPS) was associated with marked and significant reductions both in treatment failure and in mortality. The aim of this study was to confirm these results in clinical practice in the same centres of the RCT study. METHODS: Retrospective review of patients admitted for acute variceal bleeding and high risk of treatment failure (Child C<14 or Child B plus active bleeding), treated with early-TIPS (n=45) or drugs+endoscopic therapy (ET) (n=30). RESULTS: Patients treated with early-TIPS had a much lower incidence of failure to control bleeding or rebleeding than patients receiving drug+ET (3 vs 15; p<0.001). The 1-year actuarial probability of remaining free of this composite end point was 93% vs 53% (p<0.001). The same was observed in mortality (1-year actuarial survival was 86% vs 70% respectively; p=0.056). Actuarial curves of failure to control bleeding + rebleeding and of survival were well within the confidence intervals of those observed in the RCT. CONCLUSIONS: This study supports the early use of TIPS in patients with cirrhosis and a high-risk variceal bleeding.
ISSN: 0168-8278
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Hepatology

Files in This Item:

There are no files associated with this item.


All items in Lirias are protected by copyright, with all rights reserved.